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Abstract
The aim of the experiment was to study the anti-inflammatory effect of the novogalene agent Ledum 50, obtained from 
Ledum palustre shoots, in a rat model of acute bronchitis.
Materials and methods. Acute bronchitis was initiated by endotracheal administration of 1 % formalin solution. The ef-
fectiveness of Ledum 50 was investigated by the number of leukocytes and cell composition in isotonic BAL solution after 24 hours 
and after 8 days of the experiment. Serum levels of C-reactive protein (CRP), alkaline phosphatase (AP) and CIC were determined. 
Histological examination of the lungs was carried out.
Results. Endotracheal injection of formalin caused irritation of the trachea and bronchi, excessive formation of bronchial 
secretions (heavy breathing, wheezing) in all the studied groups. The lethality of animals in the OB group on the 3rd day of the expe-
riment (1 rat) was recorded, in the studied groups there was no death. The level of leukocytes in BAL after 24 hours exceeded the index 
of the IC group by 9.63 times (p < 0.05), after 8 days – by 3.0 times (p < 0.05). In the cellular composition of BAL, there was a signif-
icant increase in granulocytes (rod- and segmented neutrophils, eosinophils), monocytes and a decrease in the lymphocyte population 
against the IC group. Such changes were verified in the long term (8 days of the experiment), which indicates an inflammatory process.
In the group of rats that received Ledum 50, leukocytes in the BAL significantly decreased, the number of monocytes and 
lymphocytes in the BAL decreased, the amount of CIC in the blood serum, CRP and AP normalized. In terms of effectiveness, Le-
dum 50 significantly exceeded the BAL values of the reference drug. The effectiveness of experimental therapy for acute bronchitis 
was also verified by studying the histostructure of the airways and the respiratory part of the lungs.
Conclusions. Studies confirm the favorable course of acute bronchitis with Ledum 50 monotherapy. This fact is confirmed by 
the results of normalization of hematological parameters, leukocytes and BAL cell composition after 7 days of treatment with the claimed 
agent. This is the basis for further preclinical and clinical studies with the aim of creating an oral drug for the treatment of acute bronchitis.
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1. Introduction
Acute bronchitis (AB) is characterized by acute inflammation of the trachea and large bron-
chi without signs of pneumonia. In 90 % of cases, the causative agents of the disease are viruses, 
much less bacteria, such as: Mycoplasmapneumoniae, Bordetellapertussis and Chlamydiapneumo-
niae [1, 2]. AB can also develop due to damage to the lungs by vapors of hydrogen sulfide, chlorine, 
ammonia, organic dust and other toxic substances. The dominant signs of AB are cough, possible 
wheezing, shortness of breath, nasal congestion, headache, fever, the radiograph shows an expan-
sion of the roots of the lungs [3]. According to the guidelines on the basis of evidence-based me-
dicine, drug therapy for the treatment of acute bronchitis includes symptomatic treatment of cough, 
and it is recommended to take antitussive drugs and expectorants [4]. In our opinion, it is rational 
to use herbal medicines, because herbal medicines act on the mechanism of development of acute 
bronchitis, reducing inflammation in the respiratory tract [5, 6]. In addition, they have a number of 
advantages: polytherapy, safety, efficacy and cost-effectiveness [7, 8]. In the pharmaceutical mar-
ket of Ukraine you can find many herbal medicines that are used and intended for the treatment 
of cough in acute bronchitis. However, according to the literature, a limited number of drugs have 
a strong evidence base and are recommended for use by European colleagues. The effectiveness 
of ivy and thyme has been clinically proven [9–12], but ivy-based drugs are quite expensive, and 
thyme-based drugs have a number of contraindications, such as: diseases of the gastrointestinal 
tract (hyperacid gastritis, peptic ulcer disease), cardiovascular disease system (in atrial fibrillation, 
atherosclerosis, hypertension), in addition, the essential oil of thyme is a strong irritant to the renal 
parenchyma [13]. Since these diseases are very relevant – the use of thyme is limited.
Therefore, further search for new herbal medicines is promising. Our attention was drawn 
to a plant that has long been used in folk medicine for the treatment of respiratory diseases – shoots 
of Ledum palustre. It is known that Ledum palustre enhances the secretion of bronchial glands, 
increases the activity of the ciliated epithelium of the respiratory tract, has an antispasmodic effect 
on the smooth muscles of the bronchi, providing expectorant, enveloping and antitussive effect, has 
antimicrobial activity. Due to the poisonous properties of the plant today, its use is limited – the 
essential oil, which is part of the plant, causes headaches, dizziness, nausea. In the study, it was de-
cided to obtain a new galenic phytocomplex based on the shoots of Ledum palustre, which due to its 
purification from ballast substances will not have a toxic effect on the body. Previous studies have 
proved the author’s assumptions (experimental study of acute toxicity and the study of the effect of 
phytocomplex No. 5 on the behavioral and emotional response in rats) [14, 15].
That is why the shoots of Ledum palustre are useful as promising plant raw materials for the 
creation of new drugs in the treatment of diseases of the respiratory system. It is also worth noting 
that Ledum palustre has a raw material base in Ukraine. There are resources in the territory of 
Western Polissya (Volyn and Rivne regions) [16, 17]. 
The aim of the experiment was to investigate the anti-inflammatory effect of the new galenic 
agent Ledum 50, obtained from the shoots of Ledum palustre in a model of acute bronchitis in rats.
2. Materials and methods
At the Department of Pharmacognosy of the National University of Pharmacy under the 
leadership of prof. Koshovyi O. M., the method of multiple extraction of Ledum palustre shoots 
with 50 % ethanol [18], obtained a new galaxy phytocomplex of Ledum palustre shoots (herein-
after – Ledum 50), which includes polyphenolic compounds – 13.47 %, flavonoids – 12.34 %, 
monosaccharides – 4.79 %, carboxylic acids – 2.96 %, hydroxycinnamic acids – 1.78 %, terpene 
compounds – 1.33 % and amino acids – 0.31 %. In experiments on guinea pigs, Ledum 50 showed 
a pronounced antitussive and bronchodilator effect at a dose of 50 mg/kg [19, 20].
The next step in the study was to examine the effectiveness of Ledum 50 in acute bronchitis 
in rats [21]. White outbred female rats obtained from the vivarium of the Educational And Scien-
tific Institute Of Applied Pharmacy of NUPh were selected for the study. Animals were kept in 
a room with controlled microclimate parameters: air temperature + 18–22 °C, relative humidity 
50–65 %, light regime «12 hours day/night» [22]. Animals were treated in accordance with the 
rules of the «European Convention for the Protection of Vertebrate Animals Used for Experimental 
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and Scientific Purposes» (Strasbourg, 1986) [23]. The study protocol of Ledum 50 on the model 
of acute bronchitis was agreed with the local committee on bioethics «Commission on Bioethics 
of the National University of Pharmacy», Protocol No. 2 dated November 4, 2019, 
All experimental animals except intact were modelled with AB. As the initiating agent 
used 1 % formalin solution, which was administered endotracheally at a dose of 2 ml/animal using 
a probe for endotracheal administration under anesthesia (thiopental 38 mg/kg, intraperitoneal-
ly) (certificate No. 001528 from 15.03.2020). Animals were divided into groups: the first – in-
tact control (IC, 6 animals), the second – animals with simulated acute bronchitis (AB, 6 ani-
mals); groups 3 and 4 – animals that received simulated AB received Ledum 50 at a dose of 
50 mg/kg (6 animals) [10] and the comparison drug (CD) effervescent tablets Propan at a dose 
of 240 mg/kg (6 animals), respectively. Effervescent tablets Prospan (p.19N066A, Germany), were 
transferred from the daily dose for humans using the conversion factor [24].
Test samples were administered intragastrically once daily in a volume of 1 ml/100 g, 
group AB animals received distilled water in an equivalent volume. Treatment was started 24 hours 
after modelling AB for 7 days.
To assess the intensity of airway inflammation 24 hours (peak pathology) after AB initia-
tion [21], 6 animals from the group of intact control and the group with simulated AB were removed 
from the experiment. The level of leukocytes and ESR was determined in the peripheral blood of 
control rats, in the isotonic solution of BAL – leukocytes and the cellular composition of washes by 
conventional methods [25–27]. 
To study the effectiveness of treatment from the experiment, the animals were removed on 
the 8th day of the experiment under light chloroform anesthesia and bronchoalveolar lavage was 
taken, blood was collected for biochemical parameters and lung tissue was taken for histological 
examination.
The pharmacotherapeutic effect of the samples was determined by serum biochemical pa-
rameters – the level of C-reactive protein (CRP), the activity of alkaline phosphatase (AP) and 
circulating immune complexes (CIC) using diagnostic kits (LLC NPL «Granum», Ukraine).
Fragments of the main (extrapulmonary) and intrapulmonary bronchi and bronchioles, re-
spiratory department of lungs of rats of all experimental groups were used for histologic researches. 
Histological preparations were made according to the recommendations [28]. Examination of micro-
preparations was performed using a Granum microscope, microphotography – a digital video camera 
Granum DSM 310, photographs were processed on a Pentium 2.4 GHz computer using Toup View.
All actual material was processed by methods of variation statistics (mean value (M), its 
standard error (m) using parametric (one-way analysis of variance ANOVA, Newman-Keuls test) 
and non-parametric methods of analysis (Kruskal-Wallis test, Mann-Whitney test)). The accepted 
significance level is p < 0.05, and the standard STATISTICA software package (version 6) was used 
to obtain statistical conclusions [29–31]. 
3. Research results
Endotracheal administration of formalin caused irritation of the trachea and bronchi, exces-
sive formation of bronchial secretions (difficulty breathing, wheezing) in all experimental groups. 
Mortality of animals was recorded on the 3rd day of the experiment only in group AB (1 rat), in the 
experimental groups there was no death (Table 2).
Swelling and hemorrhage were observed in the bronchi during macro-examination. 
In group AB, the level of leukocytes in BAL (Table 1) after 24 hours exceeded this figure by 
9.63 times (p < 0.05), after 8 days – 3.0 times (p < 0.05). When assessing the cellular composition 
of BAL in these terms, a significant increase in granulocytes (segmental and rod-shaped neutro-
phils, eosinophils) and monocytes, a decrease in the population of lymphocytes relative to the 
IC group (Table 1). In all treated groups of animals, BAL leukocytes were significantly reduced 
against the AB group to the level of the IR group. Indicators of cell composition in the group receiv-
ing Ledum 50 were close to those of group IC (monocytes and lymphocytes), the total granulocyte 
showed a tendency to decrease. Prospan also had a similar effect, some indicators (segmental neu-
trophils, monocytes, lymphocytes) were even inferior to Ledum 50.
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The inflammatory process initiated by formalin, naturally led to an increase in the serum of 
animals CRP level, an important marker of bronchopulmonary diseases [32, 33], which is logically 
correlated with the maximum value of leukocytes in group AB (Table 1). In animals of group Le-
dum 50 the value of this indicator was significant against group AB and had no significant devia-
tions from the values of group IC. A similar effect is shown in the Prospan CD group. No deviations 
between the study groups were found.
Table 1
The effect of Ledum 50 and the comparison drug Prospan on the level of leukocytes and cell composition 





control AB AB + Ledum 50 AB + Prospan
24 hours 7 days of treatment
Blood leukocytes, 109/l 12.42 ± 0.62 16.85 ± 0.60* 12.21 ± 0.50 14.70 ± 0.46* 13.29 ± 0.72 13.21 ± 0.68
ESR, mm/h 1.66 ± 0.17 4.90 ± 0.40* 1.58 ± 0.24 3.30 ± 0.30* 2.25 ± 0.28t*/** 2.50 ± 0.18*/**
Leukocytes BAL, 109/l 0.19 ± 0.03 1.83 ± 0.29* 0.24 ± 0.07 0.76 ± 0.30* 0.34 ± 0.02** 0.36 ± 0.06 t**
Neutrophils: segmental BAL 4.40 ± 1.03 39.33 ± 8.64* 4.40 ± 1.03 18.60 ± 2.23* 1.20 ± 0.20*/**/*** 5.00 ± 0.32*/**
Neutrophils: rod-shaped BAL 3.40 ± 0.40 30.17 ± 4.09* 3.40 ± 0.40 26.80 ± 4.68* 8.00 ± 0.45*/** 8.40 ± 0.51*/**
Eosinophils BAL 3.00 ± 0.78 22.50 ± 3.28* 3.00 ± 0.78 18.60 ± 2.48* 12.20 ± 0.80*/** 14.60 ± 0.87*
Granulocytes BAL 10.80 ± 1.16 92.00 ± 9.53* 10.80 ± 1.16 64.00 ± 6.49* 21.40 ± 0.51*/**/*** 28.00 ± 0.63*/**
Monocytes BAL 7.20 ± 1.02 32.00 ± 2.27* 7.20 ± 1.02 29.60 ± 2.46* 8.60 ± 1.03**/*** 14.00 ± 1.22*/**
Lymphocytes BAL 85.40 ± 6.39 285.67 ± 25.63* 85.40 ± 6.39 180.60 ± 12.34* 101.80 ± 4.69**/t*** 119.40 ± 6.42*/**
Note: * – statistically significant values for the IC group, p < 0.05; ** – statistically significant values for group AB, p < 0.05; 
*** – statistically significant values for the group Prospan, p < 0.05; t – the value is close to statistical, 0.05 < p < 0.100
The severity of the humoral response was not enhanced in animals with AB – CIC was 
significantly reduced against the IC group (Table 2). Against the background of 7-day treatment 
with Ledum 50, this figure increased (8th day of the experiment), which is possible in the treat-
ment of bronchopulmonary diseases, especially in the late period, both in experiments and in 
the clinic [34–36]. It can also be assumed that high levels of CIC are observed in experimental 
groups in which the immune response was more effective. The AP index in group AB responded 
to intoxication of animals with significant IC values for animals. 7-fold administration to animals 
of the studied drugs reduced the manifestations of intoxication, but did not fully recover them. 
No deviations between the study groups were found.
Table 2
Effect of Ledum 50 and effervescent tablets Prospan on biochemical parameters in the serum of rats after 
7 days of treatment in acute bronchitis (M ± m)
Indicators Intact control AB AB + Ledum 50 AB + Prospan
Survival, % 100 83 100 100
CRP, g/l 7.00 ± 1 19.20 ± 2.94* 10.00 ± 1.27** 8.00 ± 1.27**
CIC, c.u. 0.070 ± 0.003 0.055 ± 0.003* 0.068 ± 0.003 0.063 ± 0.002
AP, nmol/l 4.22 ± 0.25 7.33 ± 0.31* 4.87 ± 0.23 t*/** 5.14 ± 0.23*/**
Note: * – statistically significant values for IC group, p < 0.05; ** – statistically significant values for group AB, p < 0.05; 
t – the value is close to statistical, 0.05 < p < 0.100 
At microscopic research at rats of IC group the wall of the main bronchial tubes (at the level of 
bifurcation) was presented by mucous, submucous, fibrocartilage and external covers. The mucous 
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membrane was lined with multilayered ciliated epithelium with a moderate number of goblet cells. 
The own plate of a mucous membrane was presented moderately, subepithelially contains a capil-
lary grid. The submucosal membrane consists of loose connective tissue, variable saturated with 
cellular material. The fibrocartilage shell contains not closed annular cartilaginous plates. The 
space between the plates was filled with bundles of smooth muscle cells with connective tissue 
layers, in which places are moderately represented lymphoid clusters (Fig. 1). Large and medium 
bronchi have cartilaginous plates. The lumen of the bronchi and bronchioles is quite wide. In the 
stroma of the bronchial tree lymphoid clusters were of various sizes. In the pulmonary parenchyma, 
the pattern of alveolar passages, alveolar cavities and sacs was normal, signs of dystelectasis and 
atelectasis, proliferative manifestations of interalveolar septa were not observed.
In group AB rats on day 8 of the experiment had hyperplasia of the epithelium of the main 
and large intrapulmonary bronchi, violation of the structure of the flickering apparatus (loosen-
ing of the apical parts of the flickering cells), infiltration of the mucous and submucosal layers of 
the bronchial wall (Fig. 2). Among the ciliated epithelium, a marked increase in goblet cells with 
glyco saminoglycans was observed (Fig. 3). The epithelial lining of the middle and small bron-
chi was not changed, but in the terminal bronchioles increased focal desquamation of epithelial 
cells was observed. Increased lymphocytic perebronchial reaction in the stroma of the bronchi-
al tree, focal clusters of lymphocytic cells perivascularly were found. Alveolar pattern of lung 
tissue was not changed, in some rats observed some thickened interalveolar septa (Fig. 4). The 
listed changes in lungs of rats of group AB are well coordinated with shifts of cellular structure 
in BAL (Table 1).
Fig. 1. A fragment of the wall of the main bronchus of an intact rat. Normal condition  
of the ciliated epithelium, stroma of the mucous membrane. Hematoxylin-eosin. ×400
Fig. 2. The wall of the main bronchus of rats from group AB. Epithelial hyperplasia,  
focal disturbance of the structure of the flickering apparatus, infiltration of the mucous and 
submucosal layers by inflammatory infiltrate cells. Hematoxylin-eosin. ×250
Ledum 50 therapy helped to minimize the signs of hyperplasia of the epithelium of the main 
and large intrapulmonary bronchi, disorders of the structure of the flickering apparatus (Fig. 5). 
However, there were clusters of goblet cells, focal infiltration of the mucous and submuco-
sal layers of the bronchial wall, increased lymphocytic peribronchial response, perivascular 
infiltration (Fig. 6). In animals treated with Prospan, a similar microscopic picture was observed 
cilia of ciliated epithelium 
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as in the Ledum 50 group – there were almost no signs of bronchial epithelial hyperplasia. No dif-
ferences were found between the groups.
Fig. 3. The wall of the large intrapulmonary bronchus of the rat from group AB.  
An increase in the number of goblet cells among the ciliated epithelium. PAS-reaction  
according to McManus. ×400
Fig. 4. The respiratory tract of rat lung tissue from group AB. Hypertrophy of peribronchial 
lymphocytic infiltrate. Hematoxylin-eosin. ×100
Fig. 5. The wall of the main bronchus of rats from the group Ledum 50: normal state  
of the ciliated epithelium. Hematoxylin-eosin, ×200
Fig. 6. Respiratory lung tissue of rats from the group Ledum 50: perivascular lymphocytic 
infiltration (d ). Hematoxylin-eosin, ×100
Almost a similar microscopic picture was observed after therapeutic administration of the 
comparison drug (Fig. 7), which indicates that the studied phytocomplex-leader from the shoots 
of Ledum palustre for some positive therapeutic effect on the histological condition of the bronchi 
after intratracheal administration of 1 % formalin solution is not inferior to the comparison drug.
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Fig. 7. Fragment of the wall of the main (a) and large intrapulmonary (b, c, d) bronchus, 
respiratory lung tissue (e) of the rat after treatment with the comparison drug Prospan:  
the condition of the ciliated epithelium is normal (a, b), a marked increase in the number  
of goblet cells among the ciliates middle bronchi (c, d), lymphocytic infiltration of the 
submucosal layer (c), perivascular lymphocytic infiltration (e): a, b, c, d – hematoxylin-eosin,  
d PAS reaction according to McManus x. а, c – ×200; b – ×250; d – ×400; e – ×100
4. Discussion of research results
A new galenic phytocomplex was obtained from the shoots of Ledum palustre, which is 
a light brown substance that was dissolved in distilled water for pharmacological research. To ob-
tain the phytocomplex №5 were used extraction with 50 % ethanol, for efficiency and maximum 
removal of BAS, which was proposed for the first time in contrast to previous studies [37].
According to the results of our study, 7-day treatment of rats with the proposed drug Ledum 
50 at a dose of 50 mg/kg, which simulated acute bronchitis, significantly normalized hematological 
parameters, leukocytes and cell composition of BAL. Histological examination showed that no dif-
ferences were found between the experimental group and the reference group. Which suggests that 
Ledum 50 has anti-inflammatory properties at the level of the drug Prospan. Thus, the prospects 
of further preclinical and clinical studies and the creation of a modern, safe, effective, economical, 
domestic drug for the treatment of acute bronchitis have been proven.
Study limitations. The content of leukotrienes and prostaglandins was not studied.
Prospects for further research. A number of experimental studies Ledum 50 proves its 
viability for further preclinical and clinical studies to develop an effective and safe drug for the 
pathogenetic treatment of acute bronchitis, which has a polytherapeutic effect on the body.
5. Conclusions
Endotracheal administration of 1 % formalin solution causes bronchopulmonary inflammation, 
which changes the histostructure of the lungs and bronchi on day 8 corresponds to the picture of acute 
toxic bronchitis. Modelling of AB caused mobilization of leukocytes in broncho-alveolar lavage fluid. 
Its maximum severity was observed in the dynamics after 24 hours and after 8 consecutive days, an 
increase in leukocytes and in the cellular composition of BAL. The main sign of an acute inflammatory 
process was a marked increase in CRP, AP against a background of reduced immune protection – CIC.
New galenic phytocomplex Ledum 50, obtained from shoots of Ledum palustre, at a dose 
of 50 mg/kg, which was administered intragastrically to rats in a treatment regimen for 7 days, 
significantly reduced leukocytes in BAL, restored the number of monocytes and lymphocytes in 
                                                                 a                                                          b
                                    c                                                         d                                                         e
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BAL, the indicators did not differ significantly from intact animals, normalized the number of 
immune complexes in serum, CRP and AP.
The results of the study confirm the favourable course of inflammatory disease on the back-
ground of Ledum 50 in monotherapy. Normalization of the histostructure of the respiratory system 
in animals treated with Ledum 50 is apparently due to the complex action of the phytocomplex, 
which has a strong anti-inflammatory effect, which is proven in the model of acute bronchitis and 
zymosan and carrageenan edema in rats (previously studied). It should be noted that the phytocom-
plex No. 5 is able to inhibit the synthesis of prostaglandins and leukotrienes, which will allow the 
pathogenetic therapy of acute inflammation of the bronchial mucosa. 
Conflict of interests
The authors declare that they have no conflicts of interest.
References
[1] Graham, W. (2018). Acute bronchitis. Can Fam Physician, 54, 238–239.
[2] Sanjay, S. (2020). Acute Bronchitis. Available at: https://www.msdmanuals.com/professional/pulmonary-disorders/acute-bron-
chitis/acute-bronchitis
[3] Unyfykovanyi klinichnyi protokol pervynnoi medychnoi dopomohy. «Kashel u doroslykh». Available at: https://kiai.com.ua/ua/
archive/2016/3 %2892 %29/pages-38-45/unifikovaniy-klinichniy-protokol-pervinnoyi-medichnoyi-dopomogi-kashel-u-doroslih-
[4] Nastanovy na zasadakh dokazovoi medytsyny. Nastanova 00129. Available at: https://guidelines.moz.gov.ua/documents/3030
[5] Kemmerich, B., Eberhardt, R., Stammer, H. (2011). Efficacy and Tolerability of a Fluid Extract Combination of Thyme Herb 
and Ivy Leaves and Matched Placebo in Adults Suffering from Acute Bronchitis with Productive Cough. Arzneimittelfor-
schung, 56 (9), 652–660. doi: http://doi.org/10.1055/s-0031-1296767 
[6] Wagner, L., Cramer, H., Klose, P., Lauche, R., Gass, F., Dobos, G., Langhorst, J. (2015). Herbal Medicine for Cough: a Systema-
tic Review and Meta-Analysis. Complementary Medicine Research, 22 (6), 359–368. doi: http://doi.org/10.1159/000442111 
[7] Yershovа, I. B., Osypova, T. F. (2016). General Requirements to the Preparation of Tinctures, Decoctions. Dosage of Phyto-
preparations. Actual Infectology, 3 (12), 123–127. doi: http://doi.org/10.22141/2312-413x.3.12.2016.81727 
[8] Harnik, T. P., Andriichuk, L. V., Harnik, K. V., Matsko, V. O., Petrysheva, V. O. (2018). Fitozasoby pry hostrykh respira-
tornykh zakhvoriuvanniakh ta nespetsyfichnykh zakhvoriuvanniakh orhaniv dykhannia. Fitoterapiia. Chasopys, 1, 19–25.
[9] Schaefer, A., Ludwig, F., Giannetti, B. M., Bulitta, M., Wacker, A. (2019). Efficacy of two dosing schemes of a liquid con-
taining ivy leaves dry extract EA 575 versus placebo in the treatment of acute bronchitis in adults. ERJ Open Research, 5 (4), 
00019–2019. doi: http://doi.org/10.1183/23120541.00019-2019 
[10] Holzinger, F., Chenot, J.-F. (2011). Systematic Review of Clinical Trials Assessing the Effectiveness of Ivy Leaf (Hedera 
Helix) for Acute Upper Respiratory Tract Infections. Evidence-Based Complementary and Alternative Medicine, 2011, 1–9. 
doi: http://doi.org/10.1155/2011/382789 
[11] Cwientzek, U., Ottillinger, B., Arenberger, P. (2011). Acute bronchitis therapy with ivy leaves extracts in a two-arm study. 
A double-blind, randomised study vs. an other ivy leaves extract. Phytomedicine, 18 (13), 1105–1109. doi: http://doi.org/10.1016/ 
j.phymed.2011.06.014 
[12] Hecker, M., Runkel, F., Voelp, A. (2002). Treatment of chronic bronchitis with ivy leaf special extract--multicenter 
post-marketing surveillance study in 1,350 patients. Forsch Komplementarmed Klass Naturheilkd, 9 (2), 77–84. doi: http:// 
doi.org/10.1159/000057269 
[13] Chebrets. Farmatsevtychna entsyklopediia. Available at: https://www.pharmencyclopedia.com.ua/article/75/chebrec
[14] Tolmachova, K., Kireyev, I., Tsemenko, K., Koshovoyi, O. (2019). Preclinical Study of Acute Toxicity of the Neogalenical 
phytocomplex from Ledum palustre shoots. Recipe, 22 (5), 688–694.
[15] Tolmachova, K. S., Kireyev, I. V., Koshoviy, O. M., Tsemenko, K. V., Botsula, I. V. (2019). The study of the emotional and be-
havioral response in rats after introduction of the neogalenical phytocomplex from Ledum palustre shoots. Clinical pharmacy, 
23 (3), 48–51. doi: http://doi.org/10.24959/cphj.19.1499 
[16] Minarchenko, V. M. (2013). The resources of medicinal plants of the Western Polissya: state, use and trends of dynamics. 
Naukovyi visnyk NLTU Ukrainy, 23 (13), 20–23.
[17] Gluschenko, L. A. (2014). The influence of some ecological factors on the crop value of Ledumpalustre L. coenopopulations. 
Chornomorskyi botanichnyi zhurnal, 10 (1), 6–14.
[18] Koshovyi, O., Upyr, T., Komissarenko, A. (2016). Phytochemical and pharmacological study of the dry extract of Labrador 
tea shoots. History, Problems and Prospects of Development of Modern Civilization. Tokyo: Tokyo University Press, 382–385.
Original Research Article:
full paper
(2021), «EUREKA: Health Sciences»
Number 2
72
Pharmacology, Toxicology and Pharmaceutical Science
[19] Tolmachova, K. S., Kireiev, I. V., Koshovyi, O. M., Upyr, T. V., Tolmachova, K. S. (2019). Pat. No. 139206 UA. Novohalenovyi 
fitokompleks z protykashlovoiu diieiu. MPK: A61K 36/45, A61K 47/10, A61K 11/14. No. u 2019 06433; declareted: 10.06.2019; 
published: 26.12.2019, Bul. No. 24, 3.
[20] Tolmachova, K. S., Kireiev, I. V., Koshovyi, O. M., Upyr, T. V., Tsemenko, K. V. (2019). Pat. No. 142410 UA. Zastosuvannia no-
vohalenovoho fitokompleksu pahoniv Bahna zvychainoho yak bronkholitychnoho zasobu dlia likuvannia hostroho bronkhitu. 
MPK: A61K 36/45, A61R 11/08, A61R 11/06 No. u 2019 09844; declareted: 16.09.2019; published: 10.06.2020, Bul. No. 11, 3. 
[21] Katelnikova, A. E., Kryshen, K. L., Makarov, V. G., Vorobeva, V. V., Pozharitskaia, O. N., Shikov, A. N. (2014). Poisk novykh 
protvovospalitelnykh sredstv na osnove kompleksa glikolizirovannykh peptidov, vydelennykh iz morskikh ezhei vida strongi-
locentrotus droebachiensis. Obzory po klinicheskoi farmakologii i lekarstvennoi terapii, 14 (4), 9–15.
[22] Kozhemiakin, Yu. M., Hromov, O. S., Filonenko, M. A., Sayfetdinova, H. A. (2002). Naukovo praktychni rekomendatsii 
z utrymannia laboratornykh tvaryn ta roboti z nymy. Kyiv: Avitsena, 156.
[23] Yevropeiska konventsiia pro zakhyst khrebetnykh tvaryn, shcho vykorystovuiutsia dlia doslidnykh ta inshykh naukovykh 
tsilei (1986). Strasburh. Available at: https://zakon.rada.gov.ua/laws/show/994_137#Text
[24] Ulanova, I. P., Sidorov, K. K., Khalepo, A. I.; Letavet, A. A.; Sanotskii, I. V. (Eds.) (1968). K voprosu ob uchete poverkhnosti 
tela eksperimentalnykh zhivotnykh pri toksikologicheskom issledovanii. Kyiv- Leningrad: Meditsina, 10, 18–25.
[25] Menshikov, V. V., Delektorskaia, L. N., Zolotnitskaia, R. P. (1987). Laboratornye metody issledovaniia v klinike. Moscow: 
Meditsina, 367.
[26] Zinovev, S. V., Semenova, G. V., Tseluiko, S. S., Chzhou, S. D., Li, Ts. (2014). Tsitokhimicheskaia kharakeristika lokalizatsii 
kationov kaltsiia natriia v kletkakh indutsirovannoi mokroty i bronkhoalveoliarnoi lavazhnoi zhidkosti u bolnykh bronkhial-
noi astmoi. Biulleten fiziologii i patologii dykhaniia, 52, 52–56.
[27] Meyer, K. C., Raghu, G., Baughman, R. P., Brown, K. K., Costabel, U., du Bois, R. M. et. al. (2012). An Official American 
Thoracic Society Clinical Practice Guideline: The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial 
Lung Disease. American Journal of Respiratory and Critical Care Medicine, 185 (9), 1004–1014. doi: http://doi.org/10.1164/
rccm.201202-0320st 
[28] Merkulov, G. A. (1969). Kurs patologogistologicheskoi tekhniki. Moscow: Meditsina, Leningr. otd-nie, 424.
[29] Lapach, S. N., Chubenko, A. V., Babich, P. N. (2001). Statisticheskie metody v mediko-biologicheskikh issledovaniiakh 
s ispolzovaniem Excel. Kyiv, 320.
[30] Osnovnye metody statisticheskoi obrabotki rezultatov farmakologicheskikh eksperimentov (2000). Rukovodstvo po eksperi-
mentalnomu (doklinicheskomu) izucheniiu novykh farmakologicheskikh veschestv. Moscow: Remedium, 349–354.
[31] Rebrova, O. Iu. (2006). Statisticheskii analiz meditsinskikh dannykh. Primenenie paketa programm Statistica. Moscow: 
MediaSfera, 312.
[32] Standartnie tsitopreparati bronkhoalveoliarnogo lavazha v issledovanii i patologii legkikh. Available at: http://www.clinlab.ru/
win/LIBRARY/JOURNLAB/lab6/j6ct2.htm
[33] Feschenko, Iu. І., Golubovska, O. A., Goncharov, K. A. (2012). Negospіtalna pnevmonіia u doroslikh osіb: etіologіia, patogenez, 
klasifіkatsіia, dіagnostika, antibakterіalna terapіia (proekt klіnіchnіi nastanov). Ch. І. Ukrainskii pulmonologіchnii zhurnal, 4, 5–13.
[34] Cazzola, M., Rogliani, P., Aliberti, S., Blasi, F., Matera, M. G. (2017). An update on the pharmacotherapeutic management of 
lower respiratory tract infections. Expert Opinion on Pharmacotherapy, 18 (10), 973–988. doi: http://doi.org/10.1080/1465656
6.2017.1328497 
[35] Nazar, O. V., Andrianova, I. V., Titomir, A. I., Kuznetsov, L. V. (2008). Immunologicheskie aspekty vnegospitalnoi pnevmonii. 
Klіnіchna іmunologіia, alergologіia, іnfektologіia, 5-2. Available at: https://kiai.com.ua/ru/archive/2008/5-2/article-230/ 
immunologicheskie-aspekty-vnegospitalnoy-pnevmonii
[36] Reheda-Furdychko, M. M., Reheda, S. M., Furdychko, L. O. (2016). Derangement of some immune values in blood at late 
period of experimen-tal pneumonia and thiotriazolin correctio. Odeskyi medychnyi zhurnal, 3, 9–11.
[37] Izotov, D. V., Tagiltsev, Iu. G., Kolesnikova, R. D. (2005). Tekhnologiia polucheniia i fiziko-khimicheskie kharakteristiki 
bagulnikovoi kondensatsionnoi vody. Tr. DalNIILKH, 38, 6–14.
© The Author(s) 2021





How to cite: Tolmachova, K., Kireiev, I., Koshoviy, O., Grashchenkova, S., Upyr, T. (2021). Experimental study of the influence of 
a neogalenical phytocomplex from the sprouts of ledum palustre on the course of acute bronchitis disease in rats. EUREKA: Health 
Sciences, 2, 64–72. doi: http://doi.org/10.21303/2504-5679.2021.001712
